Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease. The increasing incidence of both obesity and type 2 diabetes makes management of these related conditions particularly important. Conventional approaches to the management of type 2 diabetes that focus primarily on improving glycaemic control Ð notably insulin or sulphonylurea treatment Ð often lead to weight gain, which is particularly detrimental to patients with type 2 diabetes. By contrast, reducing body weight in such patients improves glycaemic control and other cardiovascular risk factors associated with the metabolic syndrome. This suggests that weight reduction is a rational option in the management of obese patients with type 2 diabetes. While reductions in body weight of approximately 10% have been achieved in some studies, this is dif®cult to achieve in real life, especially for patients with type 2 diabetes. Weight management agents such as sibutramine and orlistat, used as part of an integrated programme of diet, physical activity and behavioural therapy, are thus an attractive early option for the management of type 2 diabetes in obese patients.
Introduction
The steadily increasing incidence of type 2 diabetes in many countries is likely to make this one of the major diseases of the next millennium. It is estimated that the incidence will increase by 50% over the next 7 ± 8 y, bringing the total number of people worldwide with the disease to 150 million. In the face of an epidemic of this magnitude, it is clearly important to establish effective strategies for the management of type 2 diabetes in parallel with attempts to develop approaches that can reverse this worrying trend. Since obesity is a major risk factor for the development of type 2 diabetes, effective management of obesity is a logical and important goal. 1 There is a commonly held myth amongst physicians that type 2 diabetes is a relatively mild disease which is easily managed ( Table 1 ). The fact that type 2 diabetes usually becomes manifest in older patients has led to complacency about how strictly it should be managed and how hard one should aim to prevent associated complications. However, the fact that complications such as obesity, cardiovascular disease, hypertension and dyslipidaemia arise frequently is an unambiguous warning that type 2 diabetes is a serious illness which is all too often dif®cult to manage. Type 2 diabetes thus warrants rigorous intervention to minimise the development of complications and hence improve the quality of life and ultimately the life expectancy of these patients.
Obesity predisposes to type 2 diabetes
Obesity is one of the biggest obstacles to the management of type 2 diabetes and yet is frequently ignored by the medical profession, who often believe that they can do little to help their obese patients. This is particularly detrimental to such patients, since obesity is one of the most in¯uential risk factors for type 2 diabetes. Although obesity does not necessarily lead to the development of type 2 diabetes, epidemiological studies 2 There is evidence for a causal link between obesity and type 2 diabetes. Obesity worsens insulin resistance, one of the fundamental causes of type 2 diabetes, although the pathophysiological mechanisms remain uncertain. 3 There are particularly strong links with visceral fat; high levels of free fatty acids generated by intra-abdominal fat depots may act directly on the liver to interfere with glucose handling, insulin clearance and other vital homeostatic metabolic processes. In addition to obesity, other factorsÐ including a genetic predisposition, physical activity, pregnancy and diabetogenic drugsÐmay also contribute to the risks of type 2 diabetes.
Obesity makes a signi®cant contribution to the morbidity and mortality associated with type 2 diabetes, largely through its contribution to cardiovascular disease. In non-diabetic subjects, obesity is commonly associated with hypertension, dyslipidaemia and ultimately with atherogenesis and premature death from cardiovascular disease. These risks appear to be accentuated in diabetic subjects. For example, the risk of premature death is 10-fold greater in a diabetic person with a BMI b 36 kgam 2 , compared with a non-obese diabetic patient.
As with the prevalence of type 2 diabetes, the prevalence of obesity is increasing rapidly. At present in the UK, the incidence of obesity appears to be doubling each decade. This means that, by the year 2010, one-third of adults are likely to have clinically signi®cant obesity. Similar trends are being observed in other Westernised countries. Based on the experience of the Pima Indians, it seems likely that this obesity epidemic will be followed by an epidemic of type 2 diabetes.
Managing type 2 diabetes and obesity
Managing a patient with type 2 diabetes and obesity can be seen as a con¯ict of interests, because the most effective treatments for type 2 diabetes, that is insulin and sulphonylureas, frequently lead to weight gain ( Figure 1 ). This is one of the dangers of the conventional approach to the management of type 2 diabetes in which the disease and its associated complications are considered separately. The side-effects and metabolic effects of drugs used to manage type 2 diabetes, hypertension, dyslipidaemia and obesity frequently exacerbate the other complications. For example, if the physician focuses on achieving control of blood glucose levels with insulin or sulphonylurea therapy, this can lead to weight gain which in turn may worsen insulin resistance and other aspects of the metabolic syndrome. Exacerbation of hypertension and dyslipidaemia may then arise. On the other hand, treating hypertension with the conventional combination of bblockers and thiazides can exacerbate hyperglycaemia and worsen dyslipidaemia.
In contrast to these approaches, recent studies have shown that addressing the problem of obesity ®rst can lead to an improvement in blood glucose control which can be accompanied by a decrease in blood pressure, an increase in insulin sensitivity and favourable changes in blood lipid pro®les. Swedish and American studies of patients undergoing bariatric gastric surgery found that of the 50% of patients who had type 2 diabetes or were glucose intolerant before surgery, most patients developed normal glucose tolerance within 5 ± 6 y of surgery. 4 Thus, the successful loss of a substantial amount of weight improved glucose tolerance dramatically.
Other studies have shown that a loss of 5 ± 10% of body weight can produce statistically signi®cant bene®ts. Several studies, notably those of Wing, 5 have reported that patients achieving a loss of body weight of 5% or greater achieved a small but signi®cant decrease in HbA 1c levels, and that clinically meaningful improvements in HbA 1c can be obtained with a 10% decrease in body weight. This is comparable, for example, to the improvement in glycaemic control anticipated following the addition of a second oral antidiabetic agent.
How to achieve and maintain weight loss
Weight loss in obese patients with type 2 diabetes can therefore signi®cantly improve their clinical condition. As already emphasised, the multiple bene®cial effects of weight loss on several features of the metabolic syndrome (that is insulin resistance, hyperglycaemia, hypertension and dyslipidaemia) that contribute to atheroma mean that weight reduction is a rational and conceptually attractive option in the management of type 2 diabetes. IndeedÐin theory, at leastÐit could be preferable to using several different drugs to treat the individual disorders of this syndrome.
The target of 10% weight loss is very dif®cult for patients to achieve and maintain in real life, when relying on dietary and lifestyle modi®cation alone. This is especially the case for patients with type 2 diabetes who seem to ®nd it more dif®cult than nondiabetic patients to reduce weight. Only a few per cent of patients with newly diagnosed type 2 diabetes will be able to reduce their weight enough with standard dietetic and lifestyle advice to maintain acceptable glycaemic control without oral hypoglycaemic agents. 6 The introduction of the new anti-obesity drugs, sibutramine and orlistat, therefore constitutes an important development in the management of type 2 diabetes. Clinical trials suggest the use of either agentÐas part of an integrated programme of diet, physical activity and behavioural therapyÐcould allow approximately one-third of patients with type 2 diabetes to achieve weight loss of at least 10% of their body weight. In most patients, this would lead to a reduction in HbA 1c of up to 1%, a reduction in blood glucose levels of 1 ± 3 mmolal and favourable changes in other aspects of the metabolic disorder of this syndrome. Improvements in quality of life and life expectancy would be expected to accompany these changes.
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Conclusions
Obesity is widely regarded as a`Cinderella' problem that falls somewhere between a true disease and a cosmetic inconvenience. Diabetes is one area in which its potentially serious and ultimately lethal in¯uence is particularly obvious. Diabetologists have long ignored obesity, mainly because they have lacked the means to tackle it and because evidence of the bene®ts of weight loss have been unconvincing or buried in an unfashionable corner of the medical literature. Now that its importance is appreciated, and now that effective antiobesity drugs are becoming available, diabetes physicians can at last begin to take seriously their obligations to their obese diabetic patients.
